Mirapex - Analysis and Estimates from 2002 to 2020

GlobalData, July 2011, Pages: 35

Mirapex – Analysis and Estimates from 2002 to 2020

Summary

GlobalData’s pharmaceuticals report, “Mirapex – Analysis and Estimates from 2002 to 2020” provides Mirapex sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Parkinson's Disease market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Mirapex including historical sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of the drug including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2011-2020 for Mirapex in each of the seven major markets

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Parkinson’s Disease
2.2 Symptoms of Parkinson’s Disease
2.3 Diagnosis of Parkinson’s Disease
2.4 Parkinson’s Disease Treatment Strategies
2.5 Parkinson’s Disease Market
2.6 Epidemiology
2.7 Parkinson’s Disease by Age and Gender
2.8 Etiology
2.9 GlobalData Report Guidance
3 Parkinson’s Disease: Market Characterization
3.1 Parkinson’s Disease Market
3.2 Parkinson’s Disease Market Forecasts and CAGR
3.3 Factors Affecting Parkinson’s Disease Market
3.3.1 High Prevalence: Parkinson’s Disease is the Second Most Frequent Neurodegenerative Disorder
3.3.2 Increase in Old Age Population
3.3.3 Patent Expiry of Prominent Drugs
4 Stages of Parkinson’s Disease and Comparison of Treatments
4.1 The Hoehn and Yahr Scale
4.2 Modified Hoehn and Yahr Scale
4.3 The UPDRS
5 Staging of Parkinson’s Disease
5.1 Distribution of Parkinson’s Disease Patients by Age Groups
5.2 Distribution of Patients by Stages
6 Mirapex
6.1 Introduction
6.2 Mechanism of Action
6.3 Clinical Studies
6.3.1 Studies in Patients with Early Parkinson's Disease
6.3.2 Studies in Patients with Advanced Parkinson's Disease
6.3.3 Efficacy of Mirapex as Monotherapy in Mild to Moderate Parkinson’s Disease
6.4 Approval History of Mirapex
6.5 Factors Affecting Sales of Mirapex
6.5.1 Used in Multiple Regimens
6.5.2 Better Efficacy
6.5.3 Launch of Mirapex ER
6.5.4 Patent Expiry of Mirapex
6.5.5 Behavioral Addictions
6.6 Drug Evaluation
6.6.1 Drug Risk Benefit Score
6.6.2 Intensity of Competition
6.7 Sales Estimates
6.7.1 Target Patient Pool for Mirapex
6.7.2 Dosing
6.7.3 Market Penetration
6.7.4 Annual Cost of Therapy
6.7.5 Sales Estimates of Mirapex
7 Parkinson Disease Market: Appendix
7.1 Market Definitions
7.2 List of Abberiviations
7.3 Research Methodology
7.3.1 Coverage
7.3.2 Secondary Research
7.3.3 Forecasting
7.3.4 Number of Patients Approved to take the Drug
7.3.5 Net Penetration of Drug
7.3.6 Net Annual Dosing
7.3.7 Annual Cost of Therapy
7.3.8 Primary Research
7.3.9 Expert Panels
7.4 Drug Sales Estimates Model
7.5 Contact Us
7.6 Disclaimer
7.7 Sources

1.1 List of Tables
Table 1: Clinical Motor and Nonmotor Features of Parkinson’s Disease
Table 2: Hoehn and Yahr Stages of Parkinson’s Disease
Table 3: Hoehn and Yahr Stages of Parkinson’s Disease
Table 4: Four Items, Part 1 of UPDRS
Table 5: Thirteen Items, Part 2 of UPDRS
Table 6: Fourteen Items, Part 3 of UPDRS
Table 7: Fourteen Items, Part 3 of UPDRS
Table 8: Distribution of Parkinson’s Patients According to Hoehn and Yahr Classification
Table 9: Approval History of Mirapex
Table 10: Drug Risk Benefit Score of Mirapex
Table 11: Efficacy Comparison of Mirapex with Other Dopamine Agonists
Table 12: Efficacy Comparison of Mirapex with Other Competitors
Table 13: Dosing Schedule of Mirapex for Parkinson’s Disease
Table 14: Annual Cost of Mirapex for Parkinson’s Disease, 2010
Table 15: Mirapex, Parkinson’s Disease, Global, Sales Estimates ($m), 2002–2020
Table 16: Mirapex, Parkinson’s Disease, The US, Sales Estimates ($m), 2002–2020
Table 17: Mirapex, Parkinson’s Disease, The UK, Sales Estimates ($m), 2002–2020
Table 18: Mirapex, Parkinson’s Disease, France, Sales Estimates ($m), 2002–2020
Table 19: Mirapex, Parkinson’s Disease, Germany, Sales Estimates ($m), 2002–2020
Table 20: Mirapex, Parkinson’s Disease, Italy, Sales Estimates ($m), 2002–2020
Table 21: Mirapex, Parkinson’s Disease, Spain, Sales Estimates ($m), 2002–2020
Table 22: Mirapex, Parkinson’s Disease, Japan, Sales Estimates ($m), 2003–2020

1.2 List of Figures
Figure 1: Current Pharmacologic Therapies for Parkinson’s Disease and Their Potential Sites of Action in the CNS
Figure 2: The Age-Specific Prevalence Rates of Parkinson’s Disease in the Elderly Among Five European Countries, 2003
Figure 3: Parkinson’s Disease, Global, Market Size Estimates ($bn), 2010–2020
Figure 4: Proportion of Population 60 Years or Older, World, 1950-2050
Figure 5: Points Distribution of UPDRS
Figure 6: Distribution of Parkinson’s Disease Patients by Hoehn & Yahr Classification
Figure 7: Drug Model Diagram of Mirapex in the US, EU and Japan
Figure 8: Mirapex, Parkinson’s Disease, Global, Sales Estimates ($m), 2002–2020
Figure 9: Mirapex, Parkinson’s Disease, The US, Sales Estimates ($m), 2002–2020
Figure 10: Mirapex, Parkinson’s Disease, The UK, Sales Estimates ($m), 2002–2020
Figure 11: Mirapex, Parkinson’s Disease, France, Sales Estimates ($m), 2002–2020
Figure 12: Mirapex, Parkinson’s Disease, Germany, Sales Estimates ($m), 2002–2020
Figure 13: Mirapex, Parkinson’s Disease, Italy, Sales Estimates ($m), 2002–2020
Figure 14: Mirapex, Parkinson’s Disease, Spain, Sales Estimates ($m), 2002–2020
Figure 15: Mirapex, Parkinson’s Disease, Japan, Sales Estimates ($m), 2003–2020
Figure 16: Mirapex, Parkinson’s Disease, Global, Sales Distribution by Country (%), 2009
Figure 17: Drug Model Diagram
Figure 18: Patients Approved for the Drug

Customers who bought this item also bought

• CNS Therapeutics - Global Strategic Business Report
• Neurodegenerative Drugs - Global Strategic Business Report
• Global Parkinson's Disease Drug Pipeline Capsule - 2012 Update
• Parkinson's Disease Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020
• Global Parkinson's Disease Epidemiology and Patient Flow Analysis - 2012
• Comparative Analysis of Marketed Drugs in Major Indications - Patent Cliff to Set Off Intense Price Competition in High Volume Markets
• The Pricing and Reimbursement Environment for Neurology Drugs
• Global Parkinson's Disease Drug Pipeline Capsule - 2011
• Disease and Therapy Review: Parkinsons Disease
• Nuclear Medicine - Global Strategic Business Report